Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist

BACKGROUND: The in-situ vaccine using CpG oligodeoxynucleotide combined with OX40 agonist antibody (CpG + OX40) has been shown to be an effective therapy activating an anti-tumor T cell response in certain settings. The roles of tumor volume, tumor model, and the addition of checkpoint blockade in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieper, Alexander A., Spiegelman, Dan V., Felder, Mildred A. R., Feils, Arika S., Tsarovsky, Noah W., Zaborek, Jen, Morris, Zachary S., Erbe, Amy K., Rakhmilevich, Alexander L., Sondel, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264285/
https://www.ncbi.nlm.nih.gov/pubmed/37016127
http://dx.doi.org/10.1007/s00262-023-03433-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264285/
https://www.ncbi.nlm.nih.gov/pubmed/37016127
http://dx.doi.org/10.1007/s00262-023-03433-3

Ejemplares similares